J Gynecol Oncol.  2018 Mar;29(2):e31. 10.3802/jgo.2018.29.e31.

Major clinical research advances in gynecologic cancer in 2017

• Suh DH
• Kim M
• Lee KH
• Eom KY
• Kjeldsen M
• Mirza MR
• Kim JW

• KMID: 2404021
• DOI: http://doi.org/10.3802/jgo.2018.29.e31

Abstract

In 2017, 10 topics were selected as major clinical research advances in gynecologic oncology. For cervical cancer, efficacy and safety analysis results of a 9-valent human papillomavirus (HPV) vaccine and long-term impact of reduced dose of quadrivalent vaccine were updated. Brief introduction of KEYNOTE trials of pembrolizumab, a monoclonal antibody that blocks the interaction between programmed death (PD)-1 and its ligands, PD-L1 and PD-L2, followed. Tailored surveillance programs for gynecologic cancer related with Lynch syndrome and update on sentinel lymph node mapping were reviewed for uterine corpus cancer. For ovarian cancer, 5 topics were selected including poly(ADP-ribose) polymerases inhibitors and immunotherapy. The other potential practice changers covered in this review were lymphadenectomy in advanced disease, secondary cytoreductive surgery in recurrent disease, weekly dose-dense regimen for first-line chemotherapy, incorporation of bevacizumab maintenance in platinum-sensitive recurrent disease, and effect of platinum-free interval prolongation. Conflicting opinions of academic societies on periodic pelvic examination were introduced in conjunction with relevant literature review. For the field of radiation oncology, results of 2 big trials, The Postoperative Radiation Therapy in Endometrial Carcinoma-3 and Gynecologic Oncology Group-258, for endometrial cancer and recent advance in high-dose-rate brachytherapy for cervical cancer were reported. Topics for breast cancer covered adjuvant capecitabine after preoperative chemotherapy, adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-positive disease, olaparib for metastatic cancer in patients with a germline BRCA mutation, 20-year risks of recurrence after stopping endocrine therapy at 5 years, and contemporary hormonal contraception and the risk of breast cancer.

Keyword

Poly(ADP-ribose) Polymerase Inhibitors; Molecular Targeted Therapy; Immunotherapy; Ovarian Neoplasms; Breast Neoplasms

MeSH Terms

Bevacizumab
Brachytherapy
Breast Neoplasms
Capecitabine
Chemotherapy, Adjuvant
Colorectal Neoplasms, Hereditary Nonpolyposis
Contraception
Drug Therapy
Endometrial Neoplasms
Female
Gynecological Examination
Humans
Immunotherapy
Ligands
Lymph Node Excision
Lymph Nodes
Molecular Targeted Therapy
Ovarian Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerases
Radiation Oncology
Receptor, Epidermal Growth Factor
Recurrence
Trastuzumab
Uterine Cervical Neoplasms
Bevacizumab
Capecitabine
Ligands
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerases
Receptor, Epidermal Growth Factor
Trastuzumab